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Introduction {#sec1}
============

cAMP responsive element-binding protein 3-like 3 (CREB3L3, also named CREBH) is a basic liver-specific leucine zipper transcription factor belonging to the CREB/ATF family ([@bib21]). CREBH predominantly resides in the endoplasmic reticulum (ER). Under ER stress, CREBH is transferred to the Golgi apparatus where site 1 and site 2 proteases cleave its amino-terminal portion with its subsequent transfer to the nucleus to induce its target genes ([@bib31]). *CrebH* expression in the liver is induced in a fasted state rather than the fed state, resulting in accumulation of the nuclear form of CREBH. Previously, our group reported that transgenic mice overexpressing the nuclear form of CREBH in the liver (CREBH-Tg) resist diet-induced obesity (DIO) by remarkably increasing hepatic gene expression and plasma levels of fibroblast growth factor 21 (FGF21) ([@bib20]). CREBH-Tg mice also present improvements in hyperlipidemia, hyperglycemia, and insulin resistance in DIO mice ([@bib20]). Conversely, CREBH knockout (KO) (*CrebH*^*−/−*^) mice exhibit hypertriglyceridemia due to inefficient catalysis of triglyceride (TG) clearance by lipoprotein lipase (LPL) in blood. Hypertriglyceridemia results from the reduction of the expression of the LPL coactivators, Apolipoprotein c2 (*Apoc2*), *Apoa4*, and *Apoa5*, and the increase of the LPL inhibitor *Apoc3* in the liver ([@bib15], [@bib32]). When fed a methionine-choline-deficient diet or ketogenic diet (KD), the deficiency of CREBH results in hepatic steatosis ([@bib18], [@bib19], [@bib23]).

FGF21 is a unique member of the FGF family. It has hormone-like actions and is a key mediator of starvation by activating fatty acid oxidation and ketogenesis in the liver and lipolysis in white adipose tissue (WAT) ([@bib2], [@bib12]). FGF21 is mainly synthesized in the liver, and adipose tissues are also important organs for both the production and activity of FGF21. In adipocytes, FGF21 enhances insulin-independent glucose uptake, promotes mitochondrial oxidation, and induces secretion of adiponectin, which in turn mediates the glucose-lowering and insulin-sensitizing effects of FGF21 ([@bib3], [@bib17]). In response to the cold challenge, FGF21 is induced in adipose tissues, but not in the liver ([@bib6], [@bib10]). Deficiency of FGF21 in mice impairs cold-induced browning of inguinal WAT (iWAT), whereas recombinant FGF21 administration increases browning of iWAT and total energy expenditure in mice ([@bib6]). Recently, it was reported that plasma FGF21 levels positively correlate with the weight of iWAT in insulin-sensitive obese individuals ([@bib16]). *Fgf21*^*−/−*^ mice show less iWAT mass and are more insulin resistant when fed a high-fat diet. Plasma FGF21 upregulates adiponectin in iWAT, accompanied by an increase of M2 macrophage polarization ([@bib16]). The upregulation of plasma FGF21 levels in obesity is thought to serve as a defense mechanism to protect against systemic insulin resistance ([@bib16]). FGF21 is proposed to have therapeutic effects on obesity-related metabolic disturbances, such as insulin resistance, diabetes, and hypertriglyceridemia in *ob/ob* mice, DIO mice, and diabetic monkeys ([@bib13], [@bib29]). Similar to insulin resistance, FGF21 resistance is induced in obese mice such as DIO and *ob/ob* mice, thereby increasing plasma FGF21 levels ([@bib5]). This contributed to a decrease of βKlotho in WAT, but not in the liver of obese mice ([@bib5]). *Fgf21* expression is governed by peroxisome proliferator-activated receptor (PPAR) α and CREBH, which is induced by fasting or KD feeding ([@bib2], [@bib12], [@bib20], [@bib19]). Both CREBH and PPARα are activated in an autoloop manner in response to starvation, and thus synergistically activate *Fgf21* expression ([@bib14], [@bib20]).

Previously, we proposed that CREBH-Tg mice ameliorate the pathology of DIO mice by inducing hepatic expression and plasma levels of FGF21. In this study, by using *Fgf21*^*−/−*^ mice, we identified the FGF21-dependent or FGF21-independent effects on CREBH-mediated improvement of obesity.

Results {#sec2}
=======

FGF21 Has a Crucial Role in the Suppression of Diet-Induced Obesity in CREBH-Tg Mice {#sec2.1}
------------------------------------------------------------------------------------

In CREBH-Tg mice, body weight (BW) gain, hyperglycemia, hyperinsulinemia, and hypertriglyceridemia are clearly suppressed relative to high-fat high-sucrose (HFHS) DIO ([@bib20]). There is a possibility that these phenotypes of CREBH-Tg mice are a result of hepatic induction of *Fgf21*, a CREBH target gene ([@bib20]). To determine this notion, we generated CREBH-Tg *Fgf21*^*−/−*^ mice by crossing CREBH-Tg mice with *Fgf21*^*−/−*^ mice and then fed them with HFHS diet for 12 weeks. Consistent with the previous report ([@bib20]), BW gain was suppressed in CREBH-Tg mice compared with control wild-type (WT) mice following HFHS diet ([Figure 1](#fig1){ref-type="fig"}A). In contrast, BW of CREBH-Tg *Fgf21*^*−/−*^ mice was reversed to the levels of WT mice, although *Fgf21*^*−/−*^ mice did not show a significant increase in BW compared with WT mice ([Figure 1](#fig1){ref-type="fig"}A). There were no differences in liver weight among WT, CREBH-Tg, and CREBH-Tg *Fgf21*^*−/−*^ mice, whereas *Fgf21*^*−/−*^ mice had a higher liver weight than WT mice ([Figure 1](#fig1){ref-type="fig"}B). In accordance with BW changes, CREBH-Tg mice exhibited significantly lower epidermal WAT (eWAT) weight than WT mice but CREBH-Tg *Fgf21*^*−/−*^mice did not ([Figure 1](#fig1){ref-type="fig"}B). Thus, suppressive effect of CREBH overexpression on DIO was completely canceled out in CREBH-Tg *Fgf21*^*−/−*^ mice, indicating that fat loss effect of CREBH on a quantitative basis was mostly mediated through FGF21. There were no differences in food intake among all the groups ([Figure 1](#fig1){ref-type="fig"}C).Figure 1CREBH-Tg Mice Show Improvement of Diet-Induced ObesitySix-week-old male WT, Tg, *Fgf21*^*−/−*^, and Tg *Fgf21*^*−/−*^ mice were fed a high-fat high-sucrose (HFHS) diet for 12 weeks.(A) Body weight changes at indicated ages (n = 14--26 per group). ^a^Statistical significance between WT and Tg mice (^a^p \< 0.05, ^aa^p \< 0.01, ^aaa^p \< 0.001). ^b^Statistical significance between WT and *Fgf21*^*−/−*^ mice (^b^p \< 0.05). ^c^Statistical significance between Tg and *Fgf21*^*−/−*^ mice (^c^p \< 0.05, ^cc^p \< 0.01, ^ccc^p \< 0.001). ^d^Statistical significance between Tg and Tg *Fgf21*^*−/−*^ mice (^d^p \< 0.05, ^dd^p \< 0.01, ^ddd^p \< 0.001). ^e^Statistical significance between *Fgf21*^*−/−*^ and Tg *Fgf21*^*−/−*^ mice (^e^p \< 0.05).(B) Liver and epidermal WAT (eWAT) weights (n = 8--13).(C) Food intake (n = 4--7).(D) Plasma levels of glucose and insulin (n = 8--22).(E) Plasma levels of triglyceride (TG), total cholesterol (TC), and nonesterified fatty acids (NEFA) (n = 9--14).(F) Plasma levels of FGF21 (n = 11--12).(G) Representative pictures of liver sections stained with H&E.(H) Liver TG and TC (n = 9--14).(I) mRNA expressions of CREBH target genes, lipid, and cholesterol synthetic genes in livers were determined by real-time PCR (n = 7--12). Results are represented as means ± SEM. ∗p \< 0.05, ∗∗p \< 0.01, ∗∗∗p \< 0.001.

CREBH Overexpression Showed FGF21-Dependent Suppression of HFHS Diet-Induced Lipid Accumulation in the Liver and FGF21-Independent Amelioration of Insulin Resistance {#sec2.2}
---------------------------------------------------------------------------------------------------------------------------------------------------------------------

CREBH overexpression in WT mice was associated with a significant reduction in plasma glucose, insulin, and TG levels, whereas there were no differences in plasma total cholesterol (TC) and nonesterified fatty acid (NEFA) levels compared with WT mice ([Figures 1](#fig1){ref-type="fig"}D and 1E). Meanwhile, *Fgf21*^*−/−*^ mice showed no changes in plasma glucose or NEFA levels compared with WT mice, but had a tendency to increase plasma insulin levels, indicating insulin resistance ([Figures 1](#fig1){ref-type="fig"}D and 1E). Then, plasma glucose levels of CREBH-Tg *Fgf21*^*−/−*^ mice did not significantly change compared with those of CREBH-Tg mice or *Fgf21*^*−/−*^ mice, but CREBH-Tg *Fgf21*^*−/−*^ mice sustained significantly reduced plasma insulin levels (similar to CREBH-Tg mice and significantly lower than that of *Fgf21*^*−/−*^ mice) ([Figure 1](#fig1){ref-type="fig"}D). The data indicated that unlike obesity, amelioration of insulin resistance by CREBH overexpression is at least partially FGF21 independent. CREBH-Tg *Fgf21*^*−/−*^ mice showed no marked further changes in TG, TC, and NEFA levels compared with their respective controls ([Figure 1](#fig1){ref-type="fig"}E). Consistent with a previous report ([@bib20]), plasma FGF21 levels in CREBH-Tg mice were apparently increased compared with WT mice ([Figure 1](#fig1){ref-type="fig"}F). Morphological analysis with hematoxylin and eosin staining in the liver revealed that CREBH-Tg mice clearly had fewer and smaller lipid droplets compared with WT mice ([Figure 1](#fig1){ref-type="fig"}G). *Fgf21*^*−/−*^ mice exhibited exacerbation of hepatosteatosis with larger lipid droplets than WT mice. Additional absence of FGF21 in CREBH-Tg canceled amelioration of hepatosteatosis, but CREBH-Tg *Fgf21*^*−/−*^ mice had still smaller lipid droplets than *Fgf21*^*−/−*^ mice ([Figure 1](#fig1){ref-type="fig"}G). Consistently, the quantitative analysis revealed that liver TG was significantly reduced in CREBH-Tg mice and significantly increased in *Fgf21*^*−/−*^ mice compared with WT mice ([Figure 1](#fig1){ref-type="fig"}H). Liver TG content of CREBH-Tg *Fgf21*^*−/−*^ mice had a trend to decrease compared with *Fgf21*^*−/−*^ mice ([Figure 1](#fig1){ref-type="fig"}H). Liver TC content significantly decreased in *Fgf21*^*−/−*^ mice compared with WT mice, but no further reduction in CREBH-Tg *Fgf21*^*−/−*^ mice was observed ([Figure 1](#fig1){ref-type="fig"}H).

CREBH Increased *Fgf21* and *Apoa4* Expression in the Liver of DIO Mice {#sec2.3}
-----------------------------------------------------------------------

Consistent with the elevated plasma FGF21 levels ([Figure 1](#fig1){ref-type="fig"}F), CREBH overexpression significantly increased hepatic *Fgf21* expression compared with control WT mice and was undetectable in *Fgf21*^*−/−*^ background mice ([Figure 1](#fig1){ref-type="fig"}I). CREBH overexpression increased target gene expression of *Apoa4* and *Apoc2*, activators for LPL ([Figure 1](#fig1){ref-type="fig"}I), which contributes to a reduction in plasma TG levels. CREBH-Tg mice had a trend to reduce *Srebp-1c* expression and subsequently reduce its target gene expression of fatty acid synthase (*Fasn*) and stearoyl-coenzyme A desaturase 1 (*Scd1*) and elongation of very-long-chain fatty acid (FEN1/Elo2, SUR4/Elo3, yeast)-like 6 (*Elovl6*) in the liver compared with WT mice ([Figure 1](#fig1){ref-type="fig"}I). For cholesterol synthesis genes including *Srebf2*, 3-hydroxy-3-methylglutaryl-CoA synthase 1 (*Hmgcs1*) and 3-hydroxy-3-methylglutaryl-CoA reductase (*Hmgcr*), CREBH overexpression had no effects in both control WT and *Fgf21*^*−/−*^ mice ([Figure 1](#fig1){ref-type="fig"}I). FGF21 reciprocally changed liver TG and TC contents, whereas the effects of CREBH on hepatic lipogenic and cholesterogenic gene expression were marginal.

CREBH Induces Browning in iWAT of DIO Mice {#sec2.4}
------------------------------------------

Browning is the appearance and activation of beige adipocytes within iWAT, accompanied by induction of UCP1 ([@bib26]). As CREBH-Tg mice showed suppression of DIO-induced adiposity, we determined the changes in gene expression related to browning and lipolysis in WATs, including eWAT, iWAT, and brown adipose tissue (BAT) of each DIO mice group. Although the previous report indicated that FGF21 activates lipolysis in WATs ([@bib11]), lipolysis-related genes such as lipase and hormone-sensitive (*lipe*) and patatin-like phospholipase domain-containing 2 (*Pnpla2*) in WATs and BATs were not apparently changed by CREBH overexpression despite high plasma FGF21 levels ([Figures 2](#fig2){ref-type="fig"}A--2C). Meanwhile, gene profile in eWAT among four groups highlighted browning markers, uncoupling protein 1 (*Ucp1*), *Elovl3*, and cell death-inducing DNA fragmentation factor alpha-like effector A (*Cidea*). *Ucp1* and *Elovl3* expression was significantly increased in *Fgf21*^*−/−*^ mice, which were suppressed in CREBH-Tg *Fgf21*^*−/−*^ mice ([Figure 2](#fig2){ref-type="fig"}A). In contrast, CREBH overexpression in both control WT and *Fgf21*^*−/−*^ mice significantly increased *Cidea* expression in eWAT, which implicates FGF21-independent CREBH-specific effect on browning ([Figure 2](#fig2){ref-type="fig"}A). In iWAT, CREBH-Tg mice showed a significant increase in several browning-induced genes such as peroxisome proliferative-activated receptor, gamma, coactivator 1 alpha (*Ppargc1a*), and *Cidea*, and the subsequent increase in *Ucp1* compared with WT mice ([Figure 2](#fig2){ref-type="fig"}B), indicating that CREBH-Tg mice might induce browning and thermogenesis in iWAT. These changes were partially canceled in CREBH-Tg *Fgf21*^*−/−*^ mice, but the increase in *Ucp1* and *Cidea* were still partially maintained ([Figure 2](#fig2){ref-type="fig"}B), suggesting that CREBH-induced browning of iWAT is both FGF21 dependent and FGF21 independent presumably depending on details in browning functions. *Elovl3*, a mitochondrial function marker, was markedly increased in CREBH-Tg mice, which was completely canceled in CREBH-Tg *Fgf21*^*−/−*^ mice ([Figure 2](#fig2){ref-type="fig"}B). These results indicate that CREBH induces browning genes in iWAT by FGF21-dependent and FGF21-independent mechanisms. However, PR domain containing 16 (*Prdm16*), a master regulator for brown adipocyte differentiation, was not apparently changed in CREBH-Tg mice, indicating that CREBH-induced browning is independent of mediating the expression of PRDM16. Regarding lipolysis, *Pnpla2*, not *lipe*, was slightly increased in iWAT of CREBH-Tg mice, which was canceled in CREBH-Tg *Fgf21*^*−/−*^ mice ([Figure 2](#fig2){ref-type="fig"}B). In BAT, *Ucp1* and browning genes remained unchanged in WT and CREBH-Tg mice ([Figure 2](#fig2){ref-type="fig"}C). However, *Elovl3* expression was significantly induced in BAT of CREBH-Tg mice ([Figure 2](#fig2){ref-type="fig"}C), activating mitochondrial function and energy expenditure. This change was blunted in *Fgf21*^*−/−*^ background mice groups ([Figure 2](#fig2){ref-type="fig"}C), indicating that FGF21 governs *Elovl3* expression in BAT.Figure 2CREBH-Tg Mice Induce Browning in Inguinal WAT (iWAT) via FGF21Six-week-old male WT, Tg, *Fgf21*^*−/−*^, and Tg *Fgf21*^*−/−*^ mice were fed an HFHS diet for 2 weeks.(A--C) mRNA expressions of beige adipocyte marker genes in epidermal WAT (eWAT) (A), iWAT (B), and brown adipose tissue (BAT) (C) were determined by real-time PCR (n = 4--8).(D) UCP1 protein expression in eWAT, iWAT, and BAT from WT and Tg mice; α-tubulin was used as a loading control (n = 3).(E) UCP1 protein expression in iWAT from WT, Tg, *Fgf21*^*−/−*^, and Tg *Fgf21*^*−/−*^ mice; α-tubulin was used as a loading control (n = 5).(F) UCP1 immunostaining of iWAT from WT and Tg mice.(G) Oxygen consumption VO~2~ (NmL/h/kg) of WT, Tg, *Fgf21*^*−/−*^, and Tg *Fgf21*^*−/−*^ mice measured by the ARCO2000 System (Arcosystem) (n = 5--9).(H) The areas under the curve (AUCs) from the light, dark, and total periods in (F) (n = 5--9).(I) Rectal core temperature of WT, Tg, *Fgf21*^*−/−*^, and Tg *Fgf21*^*−/−*^ mice (n = 8--14). Results are represented as means ± SEM. ∗p \< 0.05, ∗∗p \< 0.01, ∗∗∗p \< 0.001.

We investigated UCP1 regulation at the protein level. Consistent with gene expression, UCP1 protein levels were markedly upregulated in the iWAT of CREBH-Tg mice compared with WT mice, whereas robust UCP1 protein contents in BAT were not changed between WT and CREBH-Tg mice ([Figure 2](#fig2){ref-type="fig"}D). In eWAT, UCP1 proteins were not detected ([Figure 2](#fig2){ref-type="fig"}D). FGF21 is known to induce UCP1 protein in iWAT ([@bib6]); thus, we evaluated it in CREBH-Tg *Fgf21*^*−/−*^ mice. The induction of UCP1 in iWAT of CREBH-Tg mice was canceled in CREBH-Tg *Fgf21*^*−/−*^ mice ([Figure 2](#fig2){ref-type="fig"}E). The induction of UCP1 in iWAT of CREBH-Tg mice was confirmed by immunocytochemistry using UCP1 antibodies ([Figure 2](#fig2){ref-type="fig"}F). These findings support the presumption that the induction of UCP1 in CREBH-Tg mice is mediated by FGF21.

CREBH Induces Whole-Body O~2~ Consumption Depending on FGF21 {#sec2.5}
------------------------------------------------------------

As it is predicted that thermogenesis is activated in CREBH-Tg mice, we determined the energy expenditure. The energy expenditure of 6-week-old mice fed an HFHS diet for 2 weeks was determined. Consistent with the induction of browning in iWAT, CREBH-Tg mice had higher O~2~ consumption than control WT mice throughout the day ([Figures 2](#fig2){ref-type="fig"}G and 2H). CREBH-Tg mice tended to have a higher body temperature than control WT mice ([Figure 2](#fig2){ref-type="fig"}I). These changes by CREBH overexpression were canceled in *Fgf21*^*−/−*^ background mice ([Figures 2](#fig2){ref-type="fig"}G--2I). These results indicate that CREBH resists DIO by enhancing basal metabolism and especially thermogenesis, which is dependent on FGF21.

CREBH Overexpression Improves Both Glucose Response and Insulin Response in WT and Even *Fgf21*^*−/−*^ Mice {#sec2.6}
-----------------------------------------------------------------------------------------------------------

Improvement of diet-induced insulin resistance by CREBH overexpression ([Figure 1](#fig1){ref-type="fig"}D) was further investigated by performing glucose tolerance test (GTT) and insulin tolerance test (ITT) in WT, CREBH-Tg, *Fgf21*^*−/−*^, and CREBH-Tg *Fgf21*^*−/−*^ mice fed an HFHS diet. In GTT, plasma glucose levels of *Fgf21*^*−/−*^ mice were higher than those of other groups, but other groups showed no differences in plasma glucose levels during GTT ([Figure 3](#fig3){ref-type="fig"}A). These changes were confirmed by calculating the area under the curve ([Figure 3](#fig3){ref-type="fig"}A). The data indicate that CREBH overexpression did not change glucose tolerance following an HFHS diet but ameliorated impairment by FGF21 absence. Intriguingly, plasma insulin levels of CREBH-Tg *Fgf21*^*−/−*^ mice were lower than those of WT mice but were higher than those of CREBH-Tg mice, indicating marked improvement in insulin resistance by overexpression of CREBH even in the absence of *Fgf21* ([Figure 3](#fig3){ref-type="fig"}B). Homeostasis model assessment of insulin resistance also showed that CREBH overexpression improves insulin resistance in WT and even *Fgf21*^*−/−*^ mice ([Figure 3](#fig3){ref-type="fig"}C). ITT demonstrated that the slightly slurred insulin response curve of WT mice on HFHS diet was markedly reduced in CREBH-Tg mice so that almost no increment in insulin response was necessary to maintain similar glucose excursion of WT mice ([Figure 3](#fig3){ref-type="fig"}D), indicating a profound improvement of insulin sensitivity. Similarly, CREBH-Tg *Fgf21*^*−/−*^ mice had lower plasma glucose levels than that of control WT and even *Fgf21*^*−/−*^ mice ([Figure 3](#fig3){ref-type="fig"}D). In contrast to dependence on FGF21 in amelioration of DIO, CREBH overexpression can also promote insulin response by both FGF21-dependent and FGF21-independent mechanisms with the latter more marked.Figure 3CREBH-Tg Mice Prevent HFHS-Induced Insulin Resistance Independent of FGF21(A) Plasma glucose levels during glucose tolerance test (GTT) in WT, Tg, *Fgf21*^*−/−*^, and Tg *Fgf21*^*−/−*^ mice fed 12 weeks of HFHS diet from age 6 weeks (left) and AUC (right) (n = 7--24). ^a^Statistical significance between WT and *Fgf21*^*−/−*^ mice (^a^p \< 0.05). ^b^Statistical significance between Tg and *Fgf21*^*−/−*^ mice (^b^p \< 0.05, ^bb^p \< 0.01).(B) Plasma insulin levels during GTT (n = 7--18). ^a^Statistical significance between WT and Tg mice (^aa^p \< 0.01, ^aaa^p \< 0.001). ^b^Statistical significance between WT and *Fgf21*^*−/−*^ mice (^b^p \< 0.05). ^c^Statistical significance between Tg and *Fgf21*^*−/−*^ mice (^cc^p \< 0.01, ^ccc^p \< 0.001). ^d^Statistical significance between Tg and Tg *Fgf21*^*−/−*^ mice (^d^p \< 0.05). ^e^Statistical significance between *Fgf21*^*−/−*^ and Tg *Fgf21*^*−/−*^ mice (^e^p \< 0.05, ^ee^p \< 0.01).(C) The homeostatic model assessment index of insulin resistance (HOMA-R) in WT, Tg, *Fgf21*^*−/−*^, and Tg *Fgf21*^*−/−*^ mice fed HFHS diet for 12 weeks from age 6 weeks (n = 7--18). ∗p \< 0.05, ∗∗p \< 0.01.(D) Blood glucose levels during insulin tolerance test (ITT) in WT, Tg, *Fgf21*^*−/−*^, and Tg *Fgf21*^*−/−*^ mice fed normal chow diet for 12 weeks from age 6 weeks (n = 9--25). ^a^Statistical significance between WT and Tg mice (^a^p \< 0.05, ^aaa^p \< 0.001). ^b^Statistical significance between WT and Tg *Fgf21*^*−/−*^ mice (^bb^p \< 0.01, ^bbb^p \< 0.001). ^c^Statistical significance between Tg and *Fgf21*^*−/−*^ mice (^c^p \< 0.05, ^cc^p \< 0.01). ^d^Statistical significance between *Fgf21*^*−/−*^ and Tg *Fgf21*^*−/−*^ mice (^d^p \< 0.05, ^dd^p \< 0.01). Results are represented as means ± SEM.

CREBH-Tg Mice Showed Suppression of HFHS Diet-Induced Macrophage Infiltration in eWAT {#sec2.7}
-------------------------------------------------------------------------------------

Histological analysis of eWAT using hematoxylin and eosin staining indicated that *Fgf21*^*−/−*^ mice had cell size of eWAT similar to WT mice; CREBH overexpression WT and *Fgf21*^*−/−*^ mice reduced this ([Figure 4](#fig4){ref-type="fig"}A). Interestingly, immunohistochemistry using antibody against F4/80 in eWAT showed that *Fgf21*^*−/−*^ mice induced infiltrated macrophages compared with WT mice and CREBH overexpression reduced them compared with WT and even *Fgf21*^*−/−*^ mice ([Figure 4](#fig4){ref-type="fig"}A). As FGF21 is reported to suppress inflammation in eWAT ([@bib28]), deficiency of FGF21 increased expression of genes such as CD68 antigen (*Cd68*), tumor necrosis factor (*Tnf*), chemokine (C-C motif) ligand 2 (*Ccl2*), and interleukin-6 (*Il6*) compared with WT mice ([Figure 4](#fig4){ref-type="fig"}B). These changes were consistent with an increase of macrophage infiltration in eWAT of *Fgf21*^*−/−*^ mice shown in [Figure 4](#fig4){ref-type="fig"}A. CREBH overexpression in both WT and *Fgf21*^*−/−*^ mice reduced the macrophage marker *Cd68* and inflammatory genes such as *Ccl2* and *Tnf* compared with WT and *Fgf21*^*−/−*^ mice, respectively ([Figure 4](#fig4){ref-type="fig"}B). Furthermore, CREBH overexpression significantly decreased *Il6* expression in *Fgf21*^*−/−*^ mice, and there were no changes in WT mice ([Figure 4](#fig4){ref-type="fig"}B). Therefore, the data support the fact that anti-inflammatory effects of CREBH might be FGF21 independent. BAT adipocytes of WT and *Fgf21*^*−/−*^ mice exhibited larger and unilocular lipid droplets like a WAT adipocyte ([Figure 4](#fig4){ref-type="fig"}C). CREBH overexpression suppressed these changes in both WT and *Fgf21*^*−/−*^ mice ([Figure 4](#fig4){ref-type="fig"}C). These findings suggest that the suppressive effects of CREBH on lipid accumulation in BAT are FGF21 independent. It has been known that inflammation in eWAT and BAT is associated with insulin resistance, and these observations could be a part of the FGF21-independent insulin sensitization by CREBH.Figure 4CREBH-Tg Mice Suppress the Inflammation in eWAT and Lipid Accumulation in BAT Independent of FGF21(A and C) Representative pictures of (A) epidermal WAT (eWAT) sections stained with H&E (upper) and F4/80 immunostaining (bottom) and (C) brown adipose tissue (BAT) sections stained with H&E from WT, Tg, *Fgf21*^*−/−*^, and Tg *Fgf21*^*−/−*^ mice fed an HFHS diet for 12 weeks from age 6 weeks.(B) Six-week-old male WT, Tg, *Fgf21*^*−/−*^, and Tg *Fgf21*^*−/−*^ mice were fed a normal chow or HFHS diet for 12 weeks. mRNA expressions of inflammatory genes in eWAT were determined by real-time PCR (n = 7--8). Results are represented as means ± SEM. ∗p \< 0.05, ∗∗p \< 0.01, ∗∗∗p \< 0.001.

CREBH Ameliorates Glucose Metabolism in *ob/ob* Mice, a Type 2 Diabetic Mouse Model, and FGF21-Resistant Mice {#sec2.8}
-------------------------------------------------------------------------------------------------------------

Another obese, but genetic, mouse model, *ob/ob* mice, showed FGF21 resistance with an expected and marked increase in plasma FGF21 levels ([@bib5], [@bib8]). If *ob/ob* mice overexpressing CREBH improve the pathology, it would suggest that CREBH has other target genes to ameliorate metabolic disorder except for FGF21. CREBH-Tg mice were crossed with *ob/ob* mice. There were no apparent differences in BW changes between *ob/ob* and *ob/ob*; CREBH-Tg mice (data not shown). As expected, *ob/ob* mice had higher hepatic *Fgf21* expression and plasma FGF21 levels compared with ob/+ control mice ([Figures 5](#fig5){ref-type="fig"}A and 5B). *ob/ob*; CREBH-Tg mice had a trend to increase hepatic gene expression and plasma levels of FGF21 compared with *ob/ob* mice ([Figures 5](#fig5){ref-type="fig"}A and 5B). *ob/ob*; CREBH-Tg mice showed a significant reduction in plasma glucose and insulin levels compared with *ob/ob* mice ([Figures 5](#fig5){ref-type="fig"}C and 5D). Although *ob/ob* mice have FGF21 resistance, CREBH-induced FGF21 might contribute to an improvement in glucose metabolism in *ob/ob*; CREBH-Tg mice. In GTT, CREBH overexpression in *ob/ob* mice markedly reduced plasma glucose and insulin levels compared with *ob/ob* mice ([Figures 5](#fig5){ref-type="fig"}E and 5F), indicating that glucose intolerance was improved in *ob/ob*; CREBH-Tg mice. In ITT, plasma glucose levels of *ob/ob*; CREBH-Tg mice were lower than in *ob/ob* mice, indicating that CREBH overexpression can improve insulin resistance ([Figure 5](#fig5){ref-type="fig"}G). Collectively, an improvement in glucose metabolism in CREBH overexpression in *ob/ob* mice despite FGF21 resistance was another piece of evidence that CREBH ameliorates insulin resistance regardless of FGF21.Figure 5CREBH Ameliorates Glucose Metabolism in *ob/ob* Mice(A) mRNA expressions of *Fgf21* of 10-week-old *ob/+*, Tg *ob/+*, *ob/ob*, and Tg *ob/ob* mice were determined by real-time PCR (n = 5--7).(B--D) Plasma levels of FGF21 (n = 4--6) (B), glucose (n = 5--7) (C), and insulin (n = 3--6) (D).(E and F) Plasma glucose levels (E) and insulin levels (F) during glucose tolerance test (GTT) in *ob/+*, Tg *ob/+*, *ob/ob*, and Tg *ob/ob* mice (n = 4--5).(G) Blood glucose levels during insulin tolerance test (ITT) in *ob/+*, Tg *ob/+*, *ob/ob*, and Tg *ob/ob* mice (n = 7--8). Results are represented as means ± SEM. ∗p \< 0.05, ∗∗p \< 0.01, ∗∗∗p \< 0.001.

Kiss1 as a Novel CREBH Target Gene in the Liver {#sec2.9}
-----------------------------------------------

To identify novel CREBH target genes, except for FGF21, which improves insulin sensitivity, we analyzed a combination of two different microarray datasets. One was the ratio of HFHS diet-fed CREBH-Tg to WT mice liver samples (x axis), and the other was the ratio of fed state to the fasted state (y axis) based upon the observation that CREBH is activated physiologically at fasting ([Figure 6](#fig6){ref-type="fig"}A) ([@bib4]). We identified Kisspeptin (Kiss1), a neuropeptide secreted by the liver and brain ([@bib7], [@bib24]), as a candidate CREBH gene target ([Figure 6](#fig6){ref-type="fig"}A). *Kiss1* gene expression was significantly increased in the liver of CREBH-Tg mice compared with WT mice ([Figure 6](#fig6){ref-type="fig"}B), which did not change even with deficiency of FGF21 ([Figure 6](#fig6){ref-type="fig"}B). Conversely, CREBH KO mice showed a significant reduction of *Kiss1* expression in the liver compared with WT mice in the fasting condition ([Figure 6](#fig6){ref-type="fig"}C). To determine whether CREBH directly regulates *Kiss1* expression, promoter analysis including luciferase assay, electrophoretic mobility shift assay (EMSA), and chromatin immunoprecipitation (ChIP) assay was performed. CREBH can bind to the cyclic AMP response element (CRE) sequence ([@bib19], [@bib21]). A previous report revealed that mouse *Kiss1* promoter has two CRE sites ([@bib24]). In the luciferase analysis, CREBH activated *Kiss1* promoter activity but blunted it using the Kiss1 luciferase vectors deleting two putative CRE sites ([Figure 6](#fig6){ref-type="fig"}D). Consistent with these results, CREBH bound to both the putative CREBH-binding sites using EMSA ([Figure 6](#fig6){ref-type="fig"}E). Next, we performed the ChIP assay using AML12 cells infected with adenoviral CREBH. Surely, CREBH bound to *Kiss1* promoter ([Figure 6](#fig6){ref-type="fig"}F). Taken together, these results confirmed that *Kiss1* is a target for CREBH.Figure 6*Kiss1* Is a New Target for CREBH(A) Microarray analysis from two independent datasets from liver samples. Relative gene expression of Tg mice fed HFHS diet for 12 weeks from age 6 weeks divided by WT mice fed HFHS diet for 12 weeks from age 6 weeks (log2, x axis), and WT mice fasted for 24 h divided by *ad lib* (log2, y axis).(B) mRNA expressions of *Kiss1* gene in the liver from WT, Tg, *Fgf21*^*−/−*^, and Tg *Fgf21*^*−/−*^ mice fed normal chow or HFHS diet for 12 weeks from age 6 weeks were determined by real-time PCR (n = 7--8).(C) mRNA expressions of *Kiss1* gene in 8-week-old 24-h-fasted liver from WT and *CrebH*^*−/−*^ mice were determined by real-time PCR (n = 4--9).(D) Mouse *Kiss1* promoter activity in AML 12.2 cells, as estimated by luciferase reporter assay. AML 12.2 cells were transfected with a pGL4.10-*Kiss1* reporter with 300-bp deletion series from 1000 bp and the indicated expression plasmid (n = 8).(E) EMSA analysis of the CREBH-binding sites in the *Kiss1* gene promoter. The *in vitro*-translated CREBH protein and ^32^P-labeled oligonucleotides for the CREBH-binding site 1 and site 2 were used in EMSAs.(F) Chromatin immunoprecipitation (ChIP) assays were performed with anti-hemagglutinin (HA) antibodies from Adv *GFP-* or Adv HA *CrebH*-treated AML 12.2 cells (n = 5). Results are represented as means ± SEM. ∗p \< 0.05, ∗∗∗p \< 0.001.

CREBH-Induced Kiss1 Contributes to Insulin Sensitivity {#sec2.10}
------------------------------------------------------

To determine the role of Kiss1 induced by CREBH, 7-week HFHS-diet-fed *Fgf21*^*−/−*^ and CREBH-Tg *Fgf21*^*−/−*^ mice were infected with Kiss1 knockdown adenovirus (Adv *Kiss1i*). At 4 weeks after adenovirus infection, we confirmed that *Kiss1* expression in the liver of CREBH-Tg *Fgf21*^*−/−*^ mice was reduced to the same level as that in *Fgf21*^*−/−*^ mice infected with Adv *LacZi* ([Figure 7](#fig7){ref-type="fig"}A). GTT was performed at 3 weeks after adenovirus infection. There were no differences in plasma glucose levels among all mouse genotype groups ([Figure 7](#fig7){ref-type="fig"}B). Plasma insulin levels during GTT were lower in CREBH-Tg *Fgf21*^*−/−*^ mice compared with *Fgf21*^*−/−*^ mice irrespective of adenovirus treatment ([Figure 7](#fig7){ref-type="fig"}C). At 3 weeks after adenovirus infection, ITT was performed. CREBH-Tg *Fgf21*^*−/−*^ Adv *LacZi* mice had lower plasma glucose levels than *Fgf21*^*−/−*^ Adv *LacZi* mice. Administration of Adv-Kiss1i treatment to CREBH-Tg *Fgf21*^*−/−*^ (CREBH-Tg *Fgf21*^*−/−*^ Adv *Kiss1i*) mice gave rise to consistently higher glucose levels than CREBH-Tg *Fgf21*^*−/−*^ Adv *LacZi* mice, canceling the blood glucose-lowering effect of CREBH overexpression ([Figure 7](#fig7){ref-type="fig"}D). These findings indicate that Kiss1 contributes to CREBH-induced insulin sensitivity. CREBH-Tg mice had lower plasma glucose levels than WT mice even if infected with Adv *Kiss1i* ([Figure 7](#fig7){ref-type="fig"}E). In the presence of FGF21, Adv *Kiss1i* did not suppress CREBH-induced insulin sensitivity. Taken together, FGF21 and Kiss1 might cooperate in CREBH-mediated improvement of glucose metabolism.Figure 7Adenoviral *Kiss1* Knockdown in the Liver of Tg *Fgf21*KO Mice Fed an HFHS Diet Attenuates Insulin Sensitivity(A) *Fgf21*^*−/−*^ and Tg *Fgf21*^*−/−*^ mice fed an HFHS diet for 7 weeks from age 6 weeks and then infected with Adv *LacZ*i or Adv *Kiss1*i. At 4 weeks after treatment, mRNA expressions of *Kiss1* gene in the liver from these mice were determined by real-time PCR (n = 5--7). ∗∗∗p \< 0.001.(B and C) (B) Plasma glucose levels and (C) plasma insulin levels during glucose tolerance test (GTT) in *Fgf21*^*−/−*^ and Tg *Fgf21*^*−/−*^ mice 3 weeks after treatment with Adv *LacZ*i or Adv *Kiss1*i (n = 5--7).(D) Blood glucose levels during insulin tolerance test (ITT) in *Fgf21*^*−/−*^ and Tg *Fgf21*^*−/−*^ mice 3 weeks after treatment with Adv *LacZ*i or Adv *Kiss1*i (n = 5--7). ∗Statistical significance between *Fgf21*^*−/−*^ Adv *LacZ*i and Tg *Fgf21*^*−/−*^ Adv *LacZ*i mice (∗p \< 0.05, ∗∗∗p \< 0.001). ^\#^Statistical significance between Tg *Fgf21*^*−/−*^ Adv *LacZ*i and Tg *Fgf21*^*−/−*^ Adv *Kiss1*i mice (^\#^p \< 0.05). Results are represented as means ± SEM.(E) Blood glucose levels during ITT in WT and Tg mice 3 weeks after treatment with Adv *LacZi* or Adv *Kiss1*i (n = 6--7). ^a^Statistical significance between WT Adv *LacZ*i and Tg Adv *LacZ*i mice (^a^p \< 0.05, ^aa^p \< 0.01, ^aaa^p \< 0.001). ^b^Statistical significance between WT Adv *LacZ*i and Tg Adv *Kiss1*i mice (^bb^p \< 0.01, ^bbb^p \< 0.001). ^c^Statistical significance between WT Adv *Kiss1i* and Tg Adv *LacZ*i mice (^cc^p \< 0.01). ^d^Statistical significance between WT Adv *Kiss1*i and Tg Adv *Kiss1*i mice (^dd^p \< 0.01, ^ddd^p \< 0.001). Results are represented as means ± SEM.

Discussion {#sec3}
==========

In this study, we analyzed the improvement of DIO phenotypes by CREBH overexpression described in our previous report ([@bib20]), using CREBH-Tg, *Fgf21*^*−/−*^ and CREBH-Tg *Fgf21*^*−/−*^ mice. Anti-obesity effect of CREBH was mediated by the activation of FGF21. Deficiency of FGF21 in CREBH-Tg mice canceled out CREBH-induced obesity phenotypes, confirming that FGF21 is crucial in CREBH-mediated amelioration of DIO. However, CREBH-Tg *Fgf21*^*−/−*^ mice still sustained some improved phenotypes such as the suppression of inflammation in eWAT and amelioration of insulin resistance. These phenotypes are FGF21 independent. Notably, we identified that Kiss1 is a potential novel target of CREBH to improve insulin sensitivity. Collectively, we revealed that CREBH ameliorates DIO phenotypes in FGF21-dependent and FGF21-independent mechanisms.

There are the following pieces of previous literature to support the mechanism by which FGF21 mediates the phenotypes of CREBH-Tg mice. The phenotypes of high-fat diet-induced obesity were improved in FGF21-Tg mice ([@bib22]). These phenotypes are reported to be canceled with the deficiency of βKlotho, a component of the FGF21 receptor complex, in both the hypothalamus and dorsal-vagal complex of FGF21-Tg mice ([@bib22]). Secreted FGF21 can activate the sympathetic nervous system and activate lipolysis in WATs and thermogenesis by the conversion of WAT adipocytes to beige adipocytes. FGF21 directly activates PGC-1α and in turn increases *Ucp1* expression in adipocytes, leading to an increase in thermogenesis in these cells ([@bib6]). Consistent with these reports, CREBH-Tg mice revealed a marked increase of UCP1 mRNA and protein in the iWAT, subsequently increasing energy expenditure compared with WT mice. These changes were canceled in *Fgf21*^*−/−*^ mice, thereby confirming that FGF21 mainly contributes to the thermogenic and anti-obesity phenotypes in CREBH-Tg mice.

It should be noticed that obesity mouse models, including *ob/ob*, *db/db*, and DIO mice, showed FGF21 resistance because of down-regulation of βKlotho ([@bib8]). Even though CREBH-Tg mice have chronic higher plasma FGF21 levels, CREBH-Tg overexpression kept glucose and insulin levels lower in DIO, *ob/ob*, and *dbdb* mice (data not shown). In the current study, plasma glucose- and insulin-lowering effects of CREBH were observed even in DIO-induced CREBH-Tg *Fgf21*^*−/−*^ and *ob/ob*; CREBH-Tg mice. Taken together, we hypothesized FGF21-independent pathway in improving insulin sensitivity by CREBH to identify Kiss1.

On feeding with high-fat diet, mice overexpressing Cidea in WATs develop obesity, but enhance insulin sensitivity, suggesting that these mice develop metabolic healthy obesity ([@bib1]). Likewise, CREBH overexpression increased *Cidea* expression in eWAT and iWAT of both WT and *Fgf21*^*−/−*^ mice. Although BWs of CREBH-Tg *Fgf21*^*−/−*^ mice were similar to those of *Fgf21*^*−/−*^ mice, CREBH-Tg *Fgf21*^*−/−*^ mice kept better insulin response than *Fgf21*^*−/−*^ mice. Thus, *Cidea* induction in adipose tissues might be a contributing factor to insulin sensitivity in CREBH-Tg mice.

CREBH overexpression was associated with the suppression of macrophage infiltration in eWAT of both WT and *Fgf21*^*−/−*^ background mice. Deficiency of FGF21 induced genes related to macrophages and inflammatory cytokines, but CREBH overexpression reversed these genes to the levels of WT mice. FGF21 activates Nrf2/HO-1 and suppresses nuclear factor (NF)-κB in macrophages, thereby inducing anti-inflammatory effects by enhancing Nrf2-mediated anti-oxidant capacity and suppressing NF-κB signaling pathway ([@bib30]). The effects of CREBH overexpression on macrophage infiltration are independent of FGF21. Inflammation of macrophages in eWAT is known to affect insulin sensitivity, one of the major contributors to obesity-mediated metabolic disturbances. Consistently, *Fgf21*^*−/−*^ mice showed both high glucose and insulin levels during GTT, indicating that *Fgf21*^*−/−*^ mice will likely progress to severe impairment of glucose response.

We identified *Kiss1* as a novel CREBH target gene responsible for better insulin sensitivity and glucose metabolism even in the absence of FGF21. Besides the major well-known role as a hypothalamus neuropeptide sex hormone, there have been some conflicting reports on the functions of Kiss1 in insulin action: whereas it is reported to inhibit or activate insulin secretion from the islets ([@bib9], [@bib24]), Kiss1 receptor KO mice exhibit adiposity, hyperleptinemia, and reduced energy expenditure ([@bib25]), thereby leading to glucose intolerance and obesity. These reports suggest that Kisspeptin signaling is important in peripheral tissues such as WAT and BAT, activating energy expenditure through thermogenesis. Exogenous Kiss1 administration to monkeys increases plasma adiponectin levels ([@bib27]). Adiponectin cooperates with FGF21 to improve glucose metabolism and insulin sensitivity in mice ([@bib17]). These support a possibility that the effects of CREBH on adipose tissues partially contribute to Kiss1. Consistently. the knockdown of Kiss1 in CREBH-Tg *Fgf21*^*−/−*^ mice partially canceled CREBH-mediated glucose-lowering effects in ITT, proposing that Kiss1 might be a CREBH-mediated insulin sensitizer. However, we need to further investigate the roles of Kiss1 on energy metabolism.

In this study, we revealed that CREBH increases hepatic expression and plasma levels of FGF21, leading to the activation of browning and subsequent thermogenesis in iWAT. CREBH suppresses inflammation of eWAT independent of FGF21. Moreover, CREBH induces its novel target *Kiss1* expression and then activates insulin sensitivity. Finally, we propose that hepatic CREBH improves DIO-mediated dysfunctions in peripheral tissues by improving systemic energy metabolism in FGF21-dependent and FGF21-independent mechanism. These findings indicate that CREBH has pleiotropic effects on obesity and diabetes. Further research to identify further unknown factors in FGF21-independent pathway should be the next project.

Limitations of the Study {#sec3.1}
------------------------

CREBH has pleiotropic effects on obesity and diabetes in FGF21-dependent and FGF21-independent mechanisms. We evaluated CREBH-mediated mechanisms using CREBH-Tg *Fgf21*^*−/−*^ mice. In this study, we identified that Kiss1 is a CREBH-mediated FGF21-independent insulin sensitizer. However, there are still unknown CREBH-mediated FGF21-independent mechanisms. Further research to identify further unknown factors in FGF21-independent pathway should be the next project.

Methods {#sec4}
=======

All methods can be found in the accompanying [Transparent Methods supplemental file](#mmc1){ref-type="supplementary-material"}.
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The data discussed in this publication have been deposited in NCBI\'s Gene Expression Omnibus (GEO, <http://www.ncbi.nlm.nih.gov/geo/>) and are accessible through GEO Series accession number [GSE143420](ncbi-geo:GSE143420){#intref0015} and [GSE143421](ncbi-geo:GSE143421){#intref0020}.
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